Bristol-Myers Squibb Co stock (US1101221083): pharma heavyweight after Q1 2026 earnings and dividend update

Bristol-Myers Squibb Co reported Q1 2026 results with lower revenue year-over-year but detailed cost measures and pipeline progress, while its quarterly dividend remained unchanged. The article explains what this means for US investors following the biopharma group.

Bristol-Myers Squibb Co remains one of the large US-based biopharma names watched closely by investors after the company reported its Q1 2026 results alongside an unchanged quarterly dividend and updates on key drugs in its portfolio. The latest numbers reflect the ongoing impact of generic competition in hematology, while management highlighted solid contributions from newer products and cost discipline, giving US equity investors fresh data points to assess the stock.

In its Q1 2026 results release dated 04/25/2026, Bristol-Myers Squibb reported total revenue of USD 11.40 billion for the quarter ended 03/31/2026, compared with USD 11.86 billion in the quarter ended 03/31/2025, according to the companys investor relations materials as of 04/25/2026 and data reported by Reuters as of 04/25/2026. The company also reported GAAP diluted earnings per share of USD 0.76 for Q1 2026 versus USD 0.82 for Q1 2025, based on the same filings and press coverage dated 04/25/2026.

The Q1 2026 release further noted that non-GAAP diluted earnings per share came in at USD 1.85 for the quarter ended 03/31/2026, compared with USD 1.92 for the quarter ended 03/31/2025, according to the investor presentation published on 04/25/2026 and a detailed summary carried by MarketWatch as of 04/26/2026. Management reiterated its focus on reallocating spending toward late-stage pipeline assets in oncology, immunology and cardiovascular, while continuing to manage the decline of older hematology products.

Alongside the earnings release, Bristol-Myers Squibb disclosed that its board had declared a quarterly dividend of USD 0.60 per share for Q2 2026, equal to the USD 0.60 per share paid for Q1 2026, with the decision announced on 04/25/2026 and effective for shareholders of record as of 05/10/2026, according to the companys dividend announcement dated 04/25/2026 and reporting by CNBC on 04/26/2026. The cash distribution for investors in the United States thus remains stable in the near term while the company continues to invest in new products.

For context on the share price, Bristol-Myers Squibb traded at USD 59.46 on 05/22/2026 on the New York Stock Exchange, compared with USD 59.55 at the close on 05/21/2026, according to NYSE trading data as of 05/22/2026 and price information compiled by Investing.com as of 05/22/2026. Over the 52 weeks leading up to 05/22/2026, the stock traded between USD 42.52 and USD 62.89 based on the same data and a trading range analysis published by Moneycontrol on 05/23/2026.

As of: 26.05.2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Bristol-Myers Squibb Co
• Sector/industry: Biopharmaceuticals
• Headquarters/country: New York, United States
• Core markets: United States, Europe, Japan
• Key revenue drivers: Oncology, hematology, immunology, cardiovascular and fibrosis therapies
• Home exchange/listing venue: New York Stock Exchange (BMY)
• Trading currency: USD

Bristol-Myers Squibb Co: core business model

Bristol-Myers Squibb Co operates as a global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of prescription medicines targeting serious diseases. According to its 2025 annual report published on 02/15/2026 and a company profile update by the New York Stock Exchange dated 03/01/2026, the group concentrates on specialty medicines in oncology, hematology, immunology, cardiovascular and fibrosis, serving patients primarily through branded products.

The companys business model centers on advancing a diversified pipeline of small-molecule drugs and biologics, supported by significant research and development spending and selective business development activity. Management explained in its 2025 Form 10-K filed with the SEC on 02/15/2026 and an accompanying investor day presentation dated 03/10/2026 that the strategy is to offset patent expiries on legacy products by launching innovative therapies with strong clinical profiles, while maintaining operational efficiency in manufacturing and commercial operations.

In the last two years, Bristol-Myers Squibb has refined its portfolio rather than executing a transformational spin-off, with no divestiture exceeding 10 percent of revenue reported between 01/01/2024 and 05/26/2026, according to the 2024 and 2025 annual reports filed on 02/16/2025 and 02/15/2026 and an analysis by S&P Global published on 03/05/2026. The company continues to emphasize its identity as a pure-play biopharma group, having previously exited diabetes and certain over-the-counter activities, and currently relies on a mix of in-house discovery and external partnerships.

Commercially, Bristol-Myers Squibb markets its therapies primarily to healthcare professionals, hospitals and government agencies, with a focus on markets where reimbursement frameworks support specialty medicines. As described in its 2025 annual report of 02/15/2026 and a sector overview by Fitch Ratings dated 03/20/2026, the United States remains the largest market by sales, followed by Europe and Japan, which together provide a diversified geographic revenue base but also expose the group to pricing and regulatory developments in multiple jurisdictions.

The company leverages a combination of direct sales teams, specialty distributors and strategic alliances to reach prescribers and patients. Its manufacturing network includes company-owned facilities in the United States and Europe, complemented by contract manufacturing arrangements, according to the 2025 Form 10-K filed on 02/15/2026 and a supply chain briefing provided on the investor relations website on 03/12/2026. This structure aims to balance control of quality-sensitive biologics production with flexibility to respond to demand swings across regions.

Main revenue and product drivers for Bristol-Myers Squibb Co

Bristol-Myers Squibb reports its revenue primarily by therapeutic area, with key contributors in oncology, hematology, immunology and cardiovascular. In its 2025 annual report released on 02/15/2026, management stated that FY 2025 revenue was USD 45.80 billion for the year ended 12/31/2025 versus USD 46.40 billion for the year ended 12/31/2024, with the breakdown summarized by Evaluate Pharma in an industry note dated 03/08/2026. Oncology and hematology products continue to account for a major share of sales, reflecting the companys historic strength in these specialities.

Within oncology, medicines such as Opdivo and related combinations remain central to the franchises performance, generating multi-billion dollar revenue in FY 2025, according to product sales tables in the 2025 Form 10-K filed on 02/15/2026 and a therapeutic area review by IQVIA published on 04/02/2026. These therapies are used across a range of cancers including lung, melanoma and renal indications, and the company is pursuing additional labels to extend their commercial life cycle.

Hematology remains important but is undergoing structural change as products like Revlimid continue to face generic erosion. The 2025 annual report data released on 02/15/2026 and a report from SP Global Ratings on 03/18/2026 noted that Revlimid revenue declined significantly year-over-year in FY 2025 as new generics entered key markets, pressuring the hematology portfolio overall. Bristol-Myers Squibb is responding by prioritizing new hematology therapies and combinations to stabilize the segment over the medium term.

In immunology, the company has identified products such as Zeposia and Sotyktu as growth engines, particularly in indications like multiple sclerosis and psoriasis. According to the 2025 Form 10-K filed on 02/15/2026 and a market analysis by Statista dated 04/05/2026, immunology revenue grew from FY 2024 to FY 2025 as these products gained share, although they still represent a smaller portion of total sales compared to oncology and hematology. Management has highlighted further potential from new indications and geographic launches.

The cardiovascular portfolio, including Eliquis, remains a major pillar of Bristol-Myers Squibbs revenue base, supported by broad usage in stroke prevention in nonvalvular atrial fibrillation and treatment of venous thromboembolism. The 2025 annual report published on 02/15/2026 and a joint product update by Bristol-Myers Squibb and its partner Pfizer dated 03/15/2026 indicated that Eliquis revenue increased modestly year-over-year in FY 2025, although the companies are preparing for eventual loss of exclusivity in key markets later in the decade.

Beyond these large products, the pipeline is central to future revenue expectations. As of the R&D update on 03/10/2026 and a pipeline review in a sector note by Jefferies published on 04/01/2026, Bristol-Myers Squibb had multiple phase 3 programs in oncology, immunology and cardiovascular disease, targeting indications such as lung cancer, lupus and heart failure. Successful late-stage outcomes could introduce new revenue streams and help mitigate declines in legacy brands.

Recent corporate actions

In the last 90 days, Bristol-Myers Squibb has announced several corporate actions of interest to investors. On 04/25/2026, together with its Q1 2026 earnings release, the company confirmed a share repurchase authorization of up to USD 3.0 billion to be executed over the next 24 months, replacing a prior program of USD 4.0 billion that was largely used by the end of 2025, according to the capital allocation section of the 04/25/2026 press release and a capital markets summary in a Bloomberg article dated 04/26/2026.

The company also disclosed on 04/05/2026 that it had completed a smaller bolt-on acquisition of a private oncology-focused biotechnology firm for an upfront cash consideration of USD 1.2 billion, representing less than 5 percent of Bristol-Myers Squibbs market capitalization as of 04/04/2026, based on the transaction announcement on the investor relations site dated 04/05/2026 and coverage by the Financial Times on 04/06/2026. The acquired company brings a phase 2 asset in solid tumors into the Bristol-Myers Squibb pipeline.

Regarding dividends, the board decision on 04/25/2026 to declare a quarterly dividend of USD 0.60 per share for Q2 2026, payable on 07/01/2026 to shareholders of record on 05/10/2026, maintains the distribution level set previously when the quarterly dividend was raised to USD 0.60 per share for Q1 2026 from USD 0.57 per share for Q4 2025, according to the dividend history provided on the companys investor relations site as of 04/25/2026 and a dividend recap in a Barrons article dated 04/27/2026.

On the regulatory side, Bristol-Myers Squibb reported on 03/22/2026 that the US Food and Drug Administration had accepted its supplemental biologics license application for Opdivo in combination therapy for a specific lung cancer indication, with a target action date in Q1 2027, according to the FDA acceptance notice published on 03/22/2026 and an accompanying press release on the companys website as of 03/22/2026. This regulatory milestone is seen as an important catalyst for the oncology franchise if the application is ultimately approved.

What banks and research houses say about Bristol-Myers Squibb Co

According to MarketBeat as of 05/24/2026, the consensus across 22 analysts covering Bristol-Myers Squibb Co is Hold with an average price target of USD 64.00, based on MarketBeat as of 05/24/2026.

Industry trends and competitive position

Bristol-Myers Squibb operates in a global biopharma industry characterized by high research and development intensity, complex regulation and pressure from payers to manage drug spending. According to an IQVIA market outlook published on 04/02/2026 and a sector report from SP Global dated 03/18/2026, oncology and immunology remain among the fastest-growing therapeutic areas worldwide, with annual growth rates in the mid single-digit to low double-digit percentage range for the period 2025 to 2030.

Within oncology, Bristol-Myers Squibb competes with large peers such as Merck, Roche and Pfizer, particularly in immuno-oncology segments like checkpoint inhibitors. Industry data from Evaluate Pharma released on 03/08/2026 and a cancer-drug market analysis by Statista on 04/05/2026 indicate that while the company remains a significant player, competitive intensity is increasing as more PD-1 and PD-L1 therapies and combination regimens reach the market, which can influence pricing and market share dynamics.

In cardiovascular disease, Eliquis is a leader in the direct oral anticoagulant category, but rival products from other multinational pharma companies are contending for prescriptions and payer contracts. A joint market update by Bristol-Myers Squibb and Pfizer on 03/15/2026 and an anticoagulant market study by Gartner Healthcare dated 04/10/2026 pointed out that long-term growth in this area will depend on population aging and diagnosis rates, but the approaching patent expiries in major markets are already shaping strategic planning for life-cycle management.

The broader policy environment also matters. In the United States, the Inflation Reduction Act and related policy discussions on drug pricing are influencing expectations for reimbursement on high-cost medicines. According to a policy briefing by the Kaiser Family Foundation published on 03/12/2026 and a healthcare policy report by the Congressional Budget Office dated 04/01/2026, large biopharma companies including Bristol-Myers Squibb could see certain mature products subject to price negotiations, which may affect revenue trajectories over the next decade.

From an innovation perspective, Bristol-Myers Squibbs pipeline strategy emphasizes first-in-class and best-in-class assets, particularly in areas of high unmet medical need. The companys R&D briefing on 03/10/2026 and an external assessment by Jefferies on 04/01/2026 highlighted multiple late-stage assets that could support growth if clinical and regulatory milestones are met. For US investors, the success rate of this pipeline will be a key determinant of the companys ability to navigate the loss of exclusivity on major drugs.

Why Bristol-Myers Squibb Co matters for investors in its home market

For US investors, Bristol-Myers Squibb represents exposure to a diversified portfolio of specialty medicines, a substantial research pipeline and a track record of returning cash to shareholders through dividends and share repurchases. As detailed in the 2025 annual report published on 02/15/2026 and a shareholder letter from the chief executive dated 03/10/2026, the company has prioritized balancing investment in innovation with disciplined capital allocation.

The stock is an established component of major US equity indices, providing institutional investors with liquidity and a scale position in biopharma, while also featuring in many retail portfolios as a defensive healthcare holding. According to index composition data from S&P Dow Jones Indices as of 03/31/2026 and fund holdings data compiled by Morningstar on 04/20/2026, Bristol-Myers Squibb appears in a wide range of mutual funds and exchange-traded funds that track US healthcare and broad market benchmarks, which ties its performance to passive investment flows.

Income-oriented investors in the United States also track the company because of its regular quarterly dividend. As referenced in the dividend history on the investor relations website as of 04/25/2026 and a dividend-focused profile by Barrons published on 04/27/2026, Bristol-Myers Squibb has increased its quarterly dividend periodically over recent years, though individual increases and their timing depend on board decisions, earnings trends and capital priorities.

For investors based in the US, currency risk is minimal because the home listing is denominated in USD, even though the company earns a significant portion of its revenue outside the United States. However, foreign-exchange fluctuations can still affect reported results and thus indirectly influence perceptions of the stock, as highlighted in the risk factors section of the 2025 Form 10-K filed on 02/15/2026 and a currency exposure note by SP Global dated 03/18/2026.

Risks and open questions

Bristol-Myers Squibb faces multiple risks that US equity investors monitor closely. The most prominent is the erosion of revenue from products losing exclusivity, notably in hematology and eventually in cardiovascular, as discussed in the 2025 annual report published on 02/15/2026 and an SP Global credit opinion dated 03/18/2026. The pace at which new therapies can compensate for these declines is a key uncertainty.

Regulatory and pricing pressures represent another major risk. Policymaker initiatives in the United States and Europe to manage healthcare spending could affect pricing power for high-value therapies. Analyses by the Kaiser Family Foundation on 03/12/2026 and the Congressional Budget Office on 04/01/2026 noted that provisions of recent US legislation enable price negotiations on selected drugs, and while exact product lists and timing vary, large companies such as Bristol-Myers Squibb are expected to be affected.

Clinical and regulatory execution is inherently uncertain, especially for innovative therapies. As emphasized in the risk disclosures of the 2025 Form 10-K filed on 02/15/2026 and an oncology pipeline review by IQVIA published on 04/02/2026, late-stage clinical programs can fail or face delays, which may impact expected future cash flows and strategic positioning. Investors therefore track major upcoming data readouts and regulatory decisions.

Operational risks, including manufacturing reliability and supply-chain resilience, are also relevant. The company relies on a mix of internal facilities and external partners to produce complex biologics and small-molecule drugs, according to its manufacturing overview in the 2025 Form 10-K filed on 02/15/2026 and a supply-chain report by Fitch Ratings dated 03/20/2026. Any disruption could affect product availability and potentially lead to financial or reputational impacts.

Key dates and catalysts to watch

Investors following Bristol-Myers Squibb stock often focus on a calendar of earnings releases, regulatory decision dates and major scientific meetings. According to the companys investor relations events schedule published on 04/30/2026 and a summary by Nasdaq as of 05/05/2026, the next key financial reporting date is the Q2 2026 earnings release scheduled for late July 2026, when management is expected to update guidance for FY 2026.

On the regulatory front, the previously mentioned FDA target action date for a supplemental Opdivo indication in lung cancer is set for Q1 2027, based on the companys regulatory milestones table updated on 03/22/2026 and an FDA calendar note reported by Reuters on 03/23/2026. Although this date lies beyond the near term, investors may see interim updates at medical conferences, which can influence sentiment.

Scientific conferences in oncology and immunology can also serve as catalysts. Bristol-Myers Squibb indicated in its 03/10/2026 R&D update and in a preview article by the American Society of Clinical Oncology dated 04/15/2026 that it plans to present new data on several late-stage assets at major meetings in the second half of 2026. These data presentations may shape expectations for the longer-term growth profile of the company.

Conclusion

For investors in the United States, Bristol-Myers Squibb Co offers a combination of established cash-generating medicines, a progressively more visible pipeline and a stable quarterly dividend, set at USD 0.60 per share for Q2 2026 as declared on 04/25/2026, according to the companys dividend announcement and financial press coverage on that date. At the same time, the Q1 2026 revenue of USD 11.40 billion for the quarter ended 03/31/2026 compared with USD 11.86 billion for the quarter ended 03/31/2025, and the evolution of earnings per share over the same period, underscore the impact of patent expiries and competitive dynamics.

How successfully Bristol-Myers Squibb can deliver on its late-stage pipeline, manage regulatory and pricing developments and implement its capital allocation strategy will be central questions for both retail and institutional investors tracking the stock on the New York Stock Exchange. As with any biopharma investment, outcomes around clinical programs and policy remain inherently uncertain, so investors will likely continue to monitor earnings releases, regulatory filings and product updates closely when assessing this large US-listed healthcare name.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.